Rep. Katie Porter @RepKatiePorter
Earlier this week, I demanded that @OIGatHHS investigate the approval of this new Alzheimer's drug, and I'm glad @DrWoodcockFDA agrees. Scientists opposed @US_FDA's decision, and reports showed that pharma execs worked behind the scenes to get approval despite poor results. — PolitiTweet.org
The Washington Post @washingtonpost
FDA chief calls for inspector general to review agency’s handling of controversial Alzheimer’s drug https://t.co/KmeKMilscs